Pregabalin is prescribed for nerve pain, generalised anxiety, fibromyalgia and epilepsy. For many people, it is genuinely helpful. For others, the medication begins to feel necessary in a way that goes beyond the original condition it was treating.
This doesn’t usually happen through misuse. It happens because of how pregabalin works in the brain and nervous system, and how the body adapts to its regular presence. If you’ve found it harder to reduce or stop pregabalin than you expected, that experience has a clear clinical explanation and it is more common than many people realise.
This page covers how pregabalin dependency develops, what it feels like and what support looks like when you’re ready to explore it. It also covers gabapentin, a related drug in the same class, which carries similar – though generally milder – dependency potential.
Pregabalin belongs to a class of drugs known as gabapentinoids, a type of prescription drug addiction that is more common than many people realise. It works by binding to calcium channels in the nervous system, reducing the release of excitatory neurotransmitters. This means it can produce a pronounced sense of calm, reduced anxiety and in some people, mild euphoria, particularly at higher doses.
These effects are part of why pregabalin works for anxiety and nerve pain. They are also part of why dependency develops. The brain is highly responsive to substances that reliably reduce distress or produce calm. With repeated exposure, it begins to rely on the drug for that regulation rather than generating it independently.
Tolerance develops relatively quickly with pregabalin, often within weeks of regular use. The dose that once provided relief gradually produces less effect, and higher doses or more frequent use may follow, sometimes without the person fully registering the change has happened.
The UK Misuse of Drugs Act reclassified pregabalin as a Class C controlled substance in 2019, in recognition of its significant misuse and dependency potential. Despite this, it continues to be widely prescribed, and dependency developing through legitimate medical use remains underacknowledged.
Gabapentin is prescribed for similar conditions to pregabalin and works through the same mechanism. Dependency can and does develop with gabapentin, though the risk is generally considered lower; gabapentin is less potent, less rapidly absorbed and produces less pronounced euphoric effects than pregabalin.
The pattern of dependency is similar: tolerance developing over time, difficulty reducing or stopping, withdrawal symptoms when doses are missed or reduced. If you’re here because of concerns about gabapentin rather than pregabalin, most of what follows applies equally to your situation.
Dependency tends to develop gradually, and many people only recognise it in retrospect, when they try to reduce it and find it much harder than they expected.
Some things worth noticing:
Not all of these need to be present. If reducing feels harder than you think it should, that is worth paying attention to.
When someone who has been taking pregabalin regularly reduces or stops, the nervous system – which has adapted to the drug’s presence – reacts to its absence. Withdrawal symptoms can begin within 24 to 48 hours of the last dose and vary significantly in intensity depending on how long pregabalin has been used, at what dose, and how quickly the reduction happens.
Common withdrawal experiences include:
In more severe cases, pregabalin withdrawal can cause confusion and, rarely, seizures – particularly following abrupt cessation after long-term high-dose use. This is one of the reasons stopping pregabalin suddenly is not recommended without medical guidance.
Rebound effects are also common, the original anxiety or pain condition temporarily returning at greater intensity than before, making it difficult to know whether symptoms are withdrawal or the return of the underlying condition. In practice, it is often both.
A gradual, medically supervised reduction – sometimes called a taper – is generally the safest approach. The pace of that reduction matters: slower tapers produce less intense withdrawal and give the nervous system more time to adjust. In some cases, this process is supported through a detox, which in more complex situations may take place within a structured medically supervised detox programme.
Pregabalin is frequently prescribed for generalised anxiety disorder, and many people living with anxiety, depression, PTSD or other mental health conditions have been on it for extended periods. This creates a particular complexity: the drug that was prescribed to treat the mental health condition has itself become part of the problem.
When addiction exists alongside an untreated or undertreated mental health condition – something known as dual diagnosis – addressing only the dependency without the underlying mental health picture rarely leads to stable recovery. Both need to be held together.
This is something specialist treatment programmes are designed to address, supporting both addiction and mental health together, rather than treating them separately or in sequence.
Recovery from pregabalin dependency is possible, and for most people, it does not require a dramatic or sudden change. It typically begins with understanding what has happened physiologically, which removes some of the shame and confusion, and then building a plan for reduction that is realistic and properly supported.
For some people, that process happens with GP support and outpatient monitoring. For others, particularly where dependency is longstanding, where previous attempts haven’t held, or where mental health is significantly involved, a more structured environment provides the foundation for change that self-management alone cannot.
Our guide to addiction treatment explains the different levels of support available and how to think about what might be appropriate for your situation.
If you want to speak to someone about pregabalin dependency specifically, you can contact our admissions team confidentially and without pressure, without needing to have made any treatment decisions.
Michael Williams (Mikey) is the Treatment Manager at Abbington House, where he oversees the day-to-day delivery of care and supports individuals throughout their recovery journey.
